{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:30:13Z","timestamp":1793655013029,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejphar.2025.177470","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:07:36Z","timestamp":1741345656000},"page":"177470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment"],"prefix":"10.1016","volume":"998","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-4804","authenticated-orcid":false,"given":"Jolien K.E.","family":"Veraart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-262X","authenticated-orcid":false,"given":"Sanne Y.","family":"Smith-Apeldoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177470_bib1","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.4088\/JCP.17f11738","article-title":"Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib2","article-title":"Oral ketamine for depression, 2: practical considerations","volume":"80","author":"Andrade","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib4","series-title":"Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine","author":"Bitter","year":"2011"},{"key":"10.1016\/j.ejphar.2025.177470_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jad.2019.03.075","article-title":"Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD)","volume":"251","author":"Chen","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2025.177470_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0253-7176.127258","article-title":"Acute antidepressant effects of intramuscular versus intravenous ketamine","volume":"36","author":"Chilukuri","year":"2014","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.ejphar.2025.177470_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","article-title":"(1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism","volume":"71","author":"Chowdhury","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib8","series-title":"Human Cytochrome P450 Allele Nomenclature Committee","author":"Consortium","year":"2024"},{"key":"10.1016\/j.ejphar.2025.177470_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00498254.2012.685777","article-title":"Stereoselective and regiospecific hydroxylation of ketamine and norketamine","volume":"42","author":"Desta","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejphar.2025.177470_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177470_bib12","series-title":"Assessment Report Spravato","year":"2019"},{"key":"10.1016\/j.ejphar.2025.177470_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","article-title":"Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing","volume":"71","author":"Fanta","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib14","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/dmd.117.078360","article-title":"Ketamine pharmacokinetics and pharmacodynamics are altered by P-glycoprotein and breast cancer resistance protein efflux transporters in mice","volume":"46","author":"Ganguly","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2025.177470_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bja\/70.6.666","article-title":"Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method","volume":"70","author":"Geisslinger","year":"1993","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejphar.2025.177470_sref17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","article-title":"Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression","volume":"25","author":"George","year":"2017","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib18","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.biopsych.2010.11.031","article-title":"Dose- and exposure-response to ketamine in depression","volume":"70","author":"Glue","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00228-020-03047-z","article-title":"Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review","volume":"77","author":"Glue","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177470_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","article-title":"Hydroxynorketamines: pharmacology and potential therapeutic applications","volume":"73","author":"Highland","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.177470_bib22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/clinchem\/47.9.1713","article-title":"Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples","volume":"47","author":"Hijazi","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2025.177470_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1442-2042.1995.tb00444.x","article-title":"Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator","volume":"2","author":"Ihara","year":"1995","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2025.177470_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1021\/acs.molpharmaceut.7b00627","article-title":"Affinity of ketamine to clinically relevant transporters","volume":"15","author":"Keiser","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2025.177470_bib25","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/15622975.2014.922697","article-title":"Pilot dose-response trial of i.v. ketamine in treatment-resistant depression","volume":"15","author":"Lai","year":"2014","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib27","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib28","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1111\/bcp.15467","article-title":"Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective","volume":"88","author":"Langmia","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177470_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bcp.12614","article-title":"CYP2B6\u22176 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects","volume":"80","author":"Li","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib31","article-title":"Genome-wide association study and polygenic risk score analysis of esketamine treatment response","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177470_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/acps.12572","article-title":"Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression","volume":"134","author":"Loo","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2025.177470_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib34","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2025.177470_bib35","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/15622975.2023.2169349","article-title":"Oral ketamine for depression: an updated systematic review","volume":"24","author":"Meshkat","year":"2023","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib37","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177470_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177470_bib39","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00228-013-1514-8","article-title":"Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients","volume":"69","author":"Niioka","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib40","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/ALN.0b013e318218a881","article-title":"Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration","volume":"114","author":"Noppers","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2025.177470_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1742-7843.2012.00908.x","article-title":"Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine","volume":"111","author":"Peltoniemi","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177470_bib42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","article-title":"Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression","volume":"60","author":"Perez-Ruixo","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2025.177470_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12888-019-2359-1","article-title":"Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial","volume":"19","author":"Smith-Apeldoorn","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib47","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1192\/bjo.2021.1059","article-title":"Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study","volume":"8","author":"Smith-Apeldoorn","year":"2021","journal-title":"BJPsych Open"},{"key":"10.1016\/j.ejphar.2025.177470_bib48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/02698811221084055","article-title":"The antidepressant effect and safety of non-intranasal esketamine: a systematic review","volume":"36","author":"Smith-Apeldoorn","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib49","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"9","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177470_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/09595239800187001","article-title":"Route of drug use and its implications for drug effect, risk of dependence and health consequences","volume":"17","author":"Strang","year":"1998","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.ejphar.2025.177470_bib51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bcp.13083","article-title":"Comparative performance of oral midazolam clearance and plasma 4beta-hydroxycholesterol to explain interindividual variability in tacrolimus clearance","volume":"82","author":"Vanhove","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.177470_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-238135","article-title":"Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities","volume":"14","author":"Veraart","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejphar.2025.177470_bib54","first-page":"887","article-title":"Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes","volume":"29","author":"Yanagihara","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2025.177470_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdd.336","article-title":"Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers","volume":"24","author":"Yanagihara","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejphar.2025.177470_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-Ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00008571-200301000-00004","article-title":"Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine","volume":"13","author":"Zamber","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejphar.2025.177470_bib58","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177470_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.177470_bib60","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","article-title":"(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses","volume":"176","author":"Zanos","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177470_bib61","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu(2) receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.177470_bib62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177470_bib63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ijnp\/pyx100","article-title":"Role of inflammatory bone markers in the antidepressant actions of (R)-Ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T08:47:25Z","timestamp":1746953245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925002249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":63,"alternative-id":["S0014299925002249"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177470","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177470"}}